Cargando…
Therapy Discontinuation after Myocardial Infarction
The discontinuation of recommended therapy after myocardial infarction predisposes patients to serious thrombotic complications. The aim of this study was a comprehensive analysis of permanent as well as short- and long-term discontinuation of pharmacotherapy, taking into consideration the basic gro...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7766090/ https://www.ncbi.nlm.nih.gov/pubmed/33352811 http://dx.doi.org/10.3390/jcm9124109 |
_version_ | 1783628635982266368 |
---|---|
author | Pietrzykowski, Łukasz Kasprzak, Michał Michalski, Piotr Kosobucka, Agata Fabiszak, Tomasz Kubica, Aldona |
author_facet | Pietrzykowski, Łukasz Kasprzak, Michał Michalski, Piotr Kosobucka, Agata Fabiszak, Tomasz Kubica, Aldona |
author_sort | Pietrzykowski, Łukasz |
collection | PubMed |
description | The discontinuation of recommended therapy after myocardial infarction predisposes patients to serious thrombotic complications. The aim of this study was a comprehensive analysis of permanent as well as short- and long-term discontinuation of pharmacotherapy, taking into consideration the basic groups of medications and nonadherence determinants in a one-year follow-up in post-myocardial infarction (MI) patients. Material and methods: The study was a single center cohort clinical trial with a one-year follow-up including 225 patients (73.3% men, 26.7% women) aged 62.9 ± 11.9 years. In eight cases (3.6%), the follow-up duration was less than one year due to premature death. The following factors were analyzed: lack of post-discharge therapy initiation; short-term therapy discontinuation (<30 days); long-term therapy discontinuation (≥30 days); and permanent cessation of therapy. The analysis of therapy discontinuation was performed based on prescription filling data. Results: Occupational activity (Odds Ratio (OR) 5.15; 95% Confidence interval (CI) 1.42–18.65; p = 0.013) and prior MI (OR 5.02; 95% CI 1.45–16.89; p = 0.009) were found to be independent predictors of a lack of post-discharge therapy initiation with P2Y(12) receptor inhibitors. We found no independent predictors of lack of post-discharge therapy initiation with other medications, whether analyzed separately or together. Age above 65 years (Hazard Ratio (HR)—1.59; 95% CI 1.15–2.19; p = 0.0049) and prior revascularization (HR—1.44; 95% CI 1.04–2.19; p = 0.0273) were identified as independent predictors of therapy discontinuation. Multilogistic regression analysis showed no independent predictors of the cessation of any of the medications as well as the permanent or temporary simultaneous discontinuation of all medications. Conclusions: The vast majority of post-MI patients discontinue, either temporarily or permanently, one of the essential medications within one year following myocardial infarction. The most likely medication class to be discontinued are statins. Older age and prior cardiac revascularization are independent determinants of therapy discontinuation. |
format | Online Article Text |
id | pubmed-7766090 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-77660902020-12-28 Therapy Discontinuation after Myocardial Infarction Pietrzykowski, Łukasz Kasprzak, Michał Michalski, Piotr Kosobucka, Agata Fabiszak, Tomasz Kubica, Aldona J Clin Med Article The discontinuation of recommended therapy after myocardial infarction predisposes patients to serious thrombotic complications. The aim of this study was a comprehensive analysis of permanent as well as short- and long-term discontinuation of pharmacotherapy, taking into consideration the basic groups of medications and nonadherence determinants in a one-year follow-up in post-myocardial infarction (MI) patients. Material and methods: The study was a single center cohort clinical trial with a one-year follow-up including 225 patients (73.3% men, 26.7% women) aged 62.9 ± 11.9 years. In eight cases (3.6%), the follow-up duration was less than one year due to premature death. The following factors were analyzed: lack of post-discharge therapy initiation; short-term therapy discontinuation (<30 days); long-term therapy discontinuation (≥30 days); and permanent cessation of therapy. The analysis of therapy discontinuation was performed based on prescription filling data. Results: Occupational activity (Odds Ratio (OR) 5.15; 95% Confidence interval (CI) 1.42–18.65; p = 0.013) and prior MI (OR 5.02; 95% CI 1.45–16.89; p = 0.009) were found to be independent predictors of a lack of post-discharge therapy initiation with P2Y(12) receptor inhibitors. We found no independent predictors of lack of post-discharge therapy initiation with other medications, whether analyzed separately or together. Age above 65 years (Hazard Ratio (HR)—1.59; 95% CI 1.15–2.19; p = 0.0049) and prior revascularization (HR—1.44; 95% CI 1.04–2.19; p = 0.0273) were identified as independent predictors of therapy discontinuation. Multilogistic regression analysis showed no independent predictors of the cessation of any of the medications as well as the permanent or temporary simultaneous discontinuation of all medications. Conclusions: The vast majority of post-MI patients discontinue, either temporarily or permanently, one of the essential medications within one year following myocardial infarction. The most likely medication class to be discontinued are statins. Older age and prior cardiac revascularization are independent determinants of therapy discontinuation. MDPI 2020-12-19 /pmc/articles/PMC7766090/ /pubmed/33352811 http://dx.doi.org/10.3390/jcm9124109 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Pietrzykowski, Łukasz Kasprzak, Michał Michalski, Piotr Kosobucka, Agata Fabiszak, Tomasz Kubica, Aldona Therapy Discontinuation after Myocardial Infarction |
title | Therapy Discontinuation after Myocardial Infarction |
title_full | Therapy Discontinuation after Myocardial Infarction |
title_fullStr | Therapy Discontinuation after Myocardial Infarction |
title_full_unstemmed | Therapy Discontinuation after Myocardial Infarction |
title_short | Therapy Discontinuation after Myocardial Infarction |
title_sort | therapy discontinuation after myocardial infarction |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7766090/ https://www.ncbi.nlm.nih.gov/pubmed/33352811 http://dx.doi.org/10.3390/jcm9124109 |
work_keys_str_mv | AT pietrzykowskiłukasz therapydiscontinuationaftermyocardialinfarction AT kasprzakmichał therapydiscontinuationaftermyocardialinfarction AT michalskipiotr therapydiscontinuationaftermyocardialinfarction AT kosobuckaagata therapydiscontinuationaftermyocardialinfarction AT fabiszaktomasz therapydiscontinuationaftermyocardialinfarction AT kubicaaldona therapydiscontinuationaftermyocardialinfarction |